Led · Seed · Aug 2026

Kantoko operates a digital platform that provides end-to-end ADHD care by linking patients to a dedicated clinical team for diagnosis, treatment and ongoing management. Launched in 2023 by Zac Altman, the service is already serving thousands of patients and reports that 60% of its users are women and about 20% come from regional and rural areas. The platform’s pricing is $200 for the first month and $100 per month thereafter. Kantoko aims to address under-diagnosis and long wait times by offering continuous GP-led care through an integrated service. The company raised $3.5 million in an oversubscribed seed round to expand its clinical network and accelerate platform development. Founder Zac Altman previously co-founded LoungeBuddy, which was acquired in 2019.

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series A · Jun 2025

Antares Therapeutics applies a proprietary covalent discovery engine—including proprietary screening libraries, chemoproteomics, structure‑guided computational chemistry and machine‑learning tools—to identify challenging, high‑value oncology targets. The company will lead discovery work on a limited set of historically undruggable targets under a collaboration with Novartis while continuing to advance its owned and partnered portfolio of precision cancer and other serious‑disease medicines. Financially, the collaboration provided a $105 million upfront payment and the potential for up to $1.8 billion in additional milestone payments and tiered royalties if programs progress and commercialize. The partnership is intended to pair Antares’ discovery capabilities with Novartis’ development and global commercialization resources to accelerate translation of its science into therapies.

Participated · Seed · Dec 2024

Proton is developing a small device designed to be inserted just below the skin to continuously monitor potassium levels and pair with a smartphone app for patient alerts. A clinician dashboard is planned so care teams can view potassium trends and fine-tune therapies, potentially reducing in-clinic potassium testing, time, and costs. The company targets patients with chronic kidney disease and those at risk of heart failure, where potassium imbalances can be life‑threatening. Clinical trials are underway for the product, which Proton says is due to launch in 2025. The founders are CEO Sahan Ranamukhaarachchi (based in Vancouver) and CSO Victor Cadarso (based in Melbourne); the company has a commercial HQ in Canada and an R&D subsidiary in Melbourne, Australia. Proton positions its approach against other emerging potassium-monitoring firms and claims greater scalability, usability, and clinical impact.

Led · Seed · Jun 2024

Psylo is a biotechnology company focused on developing next-generation neuroplastogens, led by CEO Joshua Ismin and CSO Samuel Banister. Its flagship candidate is PSYLO-100X, a non-hallucinogenic 5-HT2A agonist intended to treat depression and other mental health disorders. The company’s platform has produced a candidate designed for safe at-home administration without clinical supervision. Psylo plans to use the newly raised capital to accelerate advancement of PSYLO-100X through development activities. The company raised $8M in Seed funding to support these efforts. Leadership frames the raise as validation of Psylo’s translational approach and the therapeutic potential of its pipeline. Psylo is developing novel mental-health therapeutics inspired by psychedelic compounds such as psilocybin. The company leverages AI and computational chemistry to design and streamline molecules intended to deliver the proposed therapeutic benefits of psychedelics without hallucinogenic effects. Psylo aims to apply these approaches to treat mental illness as an alternative to traditional antidepressants. At the Purpose Conference in Sydney the company noted that Australians are heavy users of traditional antidepressants, which it said are only about 20% more effective than placebo. Psylo has raised $5 million in a seed funding round to advance its therapeutic development and operations. The seed capital is intended to support its drug-design and development efforts.